Antioxidants, a safe and viable Inhibition Strategy for Nitrosamine Formation In Drug Products

When it comes to medical product discovery, development, and delivery, patients need to be front and center but how close (or far away) are we from truly having a system that routinely measures what matters to patients? A panel of industry, regulatory, and patient leaders will discuss what’s next for patient-centered measurement. Panelists will define patient-centered measurement; identify novel strategies for capturing patient-centered outcomes; assess the progress in product development, regulatory approval, and delivery; and address how to advance the science of patient input in a way that fulfills the unmet needs of patients across diseases.

Many orally administered small molecules have low aqueous solubility, which leads to poor oral absorption. For many of these poorly soluble drugs currently in development, amorphous dispersions are increasingly being used as a formulation approach to improve solubility and oral absorption.

Speed and quality are key in pharmaceutical manufacturing. How can your equipment add value to your production process? Join the Lonza team to discover how the new Lonza Engine™ equipment portfolio is designed to support bioavailability enhancement, encapsulation and early-phase clinical development technologies.

In the last 20 years Hot Melt Extrusion (HME) has seized the attention of pharmaceutical industry for the development of pharmaceutical solid dispersions. It is a versatile processing technology, which can effectively increase the solubility/dissolution of water insoluble active pharmaceutical ingredients (APIs).